The Contribution of Epigenetics to Cancer Immunotherapy
Por:
Villanueva, L, Alvarez-Errico, D and Esteller, M
Publicada:
1 ago 2020
Resumen:
Effective anticancer immunotherapy treatments constitute a qualitative leap in cancer management. Nonetheless, not all patients benefit from such therapies because they fail to achieve complete responses, suffer frequent relapses, or develop potentially life-threatening toxicities. Epigenomic signatures in immune and cancer cells appear to be accurate and promising predictors of patient out-comes with immunotherapy. In addition, combined treatments with epigenetic drugs can exploit the dynamic nature of epigenetic changes to potentially modu-late responses to immunotherapy. Candidate epigenetic biomarkers may provide a rationale for patient stratification and precision medicine, thus maximizing the chances of treatment success while minimizing unwanted effects. We present a comprehensive up-to-date view of potential epigenetic biomarkers in immuno-therapy and discuss their advantages over other indicators.
Filiaciones:
:
Josep Carreras Leukemia Res Inst IJC, Barcelona, Catalonia, Spain
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Alvarez-Errico, D:
Josep Carreras Leukemia Res Inst IJC, Barcelona, Catalonia, Spain
:
Josep Carreras Leukemia Res Inst IJC, Barcelona, Catalonia, Spain
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Catalonia, Spain
Univ Barcelona UB, Sch Med & Hlth Sci, Physiol Sci Dept, Barcelona, Catalonia, Spain
Green Published, hybrid
|